CHENGDU, China, 28 de agosto de 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) ha anunciado hoy sus resultados provisionales para el primer semestre de 2024, junto con una actualización corporativa. Rápido desarrollo de nuestros productos en tramitación Stapokibart (CM310)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.